Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MLC901
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : PT Ferron Par Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Moleac Announces PT Ferron Par Pharmaceuticals As New Exclusive Partner in Indonesia
Details : Under the partnership, PT Ferron Par Pharmaceuticals will become Moleac's exclusive partner in Indonesia of NeuroAiD II MLC901 which consists of extracts from 9 herbal components.
Product Name : NeuroAiD II
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
October 21, 2024
Lead Product(s) : MLC901
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : PT Ferron Par Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : MLC1501
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MLC1501 Study Assessing Efficacy in Post STrOke Subjects with MOtor Deficits
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : MLC1501
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATHENE study results support the benefit of NeuroAiD™II (MLC901) as a safe add-on therapy to standard AD treatment as the study found no evidence of a significant increase in adverse events between MLC901 and placebo.
Product Name : NeuroAiD II
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 21, 2022
Lead Product(s) : MLC1501
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MLC1501 Study Assessing Efficacy in STROke Recovery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : MLC1501
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Neuroaid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NeuroAiD IIâ„¢ (MLC901) in Mild Traumatic Brain Injury
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 27, 2021
Lead Product(s) : Neuroaid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MLC1501
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Moleac
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : MLC1501
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Moleac
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Neuroaid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 02, 2015
Lead Product(s) : Neuroaid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable